Treatment of HCV in HCC Patients After Liver Transplantation Improves Survival and Decreases Risk of HCC Recurrence

Niyazi, Fadi; Sanghi, Vedha; Abduljawad, Baraa; Asfari, Mohammad Maysara; López, Rocío; Menon, Krishna; Romero‐Marrero, Carlos

doi:10.1016/s0016-5085(17)33716-2

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Direct-acting antivirals therapy on overall survival of hepatocellular carcinoma patients. OS data was reported in nine studies involving 1190 patients receiving DAAs therapy, [21][22][23][24][25][26][27][28] 135 patients receiving IFN therapy, and 1323 patients receiving no intervention (Table 2). Nine studies compared OS between the DAAs group and the no intervention group.…”

Section: Direct-acting Antivirals Therapy On Risk Of Hepatocellular C...mentioning

confidence: 99%

Clinical benefits of direct‐acting antivirals therapy in hepatitis C virus patients with hepatocellular carcinoma: A systematic review and meta‐analysis

Liu

Yang

Dong

et al. 2022

J of Gastro and Hepatol

View full text Add to dashboard Cite

Background and Aim:The purpose of the present study was to evaluate the effect of direct-acting antivirals (DAAs) therapy on the clinical outcomes of hepatitis C virus (HCV) patients with hepatocellular carcinoma (HCC). Methods: We searched multiple electronic databases from database inception to June 14, 2021. Meta-analyses were performed separately for HCC recurrence and overall survival (OS). Results: A total of 23 studies were identified for the primary analysis. Compared with no intervention, pooled data showed significant benefit from DAAs therapy in reducing recurrence (adjusted HR = 0.55, 95% CI 0.41-0.74, P < 0.001; I 2 = 66.6%, P < 0.001) and improving OS (adjusted HR = 0.36, 95% CI 0.16-0.83, P = 0.017; I 2 = 90.7%, P < 0.001) of HCV-related HCC patients. Compared with non-responders, patients with sustained virologic response (SVR) had greater benefit from DAAs therapy in reducing recurrence (HR = 0.37, 95% CI 0.16-0.84, P = 0.017; I 2 = 58.8%, P = 0.088) and improving OS (HR = 0.17; 95% CI 0.06-0.50; P = 0.001; I 2 = 56.4%, P = 0.130). Though DAAs did not show significant advantages over IFN in reducing recurrence (adjusted HR = 0.96, 95% CI 0.72-1.28, P = 0.784; I 2 = 0.0%, P = 0.805), there seems to be a trend toward OS benefit from DAAs therapy (adjusted HR = 0.11, 95% CI 0.01-1.19, P = 0.059). Conclusion: DAAs therapy can prevent recurrence and improve OS of HCV-related HCC patients, especially for patients with SVR. Further prospective randomized controlled trial is warranted to validate these results.

show abstract

Section: Direct-acting Antivirals Therapy On Risk Of Hepatocellular C...mentioning

confidence: 99%

Clinical benefits of direct‐acting antivirals therapy in hepatitis C virus patients with hepatocellular carcinoma: A systematic review and meta‐analysis

Liu

Yang

Dong

et al. 2022

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

Treatment of HCV in HCC Patients After Liver Transplantation Improves Survival and Decreases Risk of HCC Recurrence

Cited by 1 publication

References 0 publications

Clinical benefits of direct‐acting antivirals therapy in hepatitis C virus patients with hepatocellular carcinoma: A systematic review and meta‐analysis

Clinical benefits of direct‐acting antivirals therapy in hepatitis C virus patients with hepatocellular carcinoma: A systematic review and meta‐analysis

Contact Info

Product

Resources

About